Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04858412
Other study ID # 20-1194
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date March 31, 2025

Study information

Verified date January 2024
Source The Cleveland Clinic
Contact Annette Bellar, MSLA
Phone 216-445-0688
Email bellara@ccf.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with anabolic properties, increases muscle mass and contractile function and enhances immune function. We aim to study the natural course of COVID-19 in patients with ALD and test whether HMB can affect ventilatory deterioration and improve short and long-term morbidity, mortality, and recovery from critical illness in symptomatic COVID-19 patients with ALD.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date March 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: A. Cases: Patients with ALD and COVID-19 pneumonia: 1. Clinical, imaging, laboratory, and/or histological diagnosis of alcoholic cirrhosis and/or alcoholic hepatitis 2. Child Pugh score 5-8, serum creatinine <3, Model for End Stage Liver Disease score (MELD) <25 3. Diagnosis of COVID-19 pneumonia as defined by the WHO criteria: confirmed SARS-CoV-2 infection by PCR, evidence of bilateral pulmonary infiltrates on chest radiograph (CXR) or computed tomography (CT) and SpO2 <93% or on oxygen supplement 4. Age of 21 years or older B. Controls: Patients without alcoholic liver disease (Non-ALD) and COVID-19 pneumonia: 1. Diagnosis of COVID-19 pneumonia as defined by the WHO criteria: confirmed SARS-CoV-2 infection by PCR, evidence of bilateral pulmonary infiltrates on chest radiograph (CXR) or computed tomography (CT) and SpO2 <93% or on oxygen supplement 2. Age of 21 years or older Exclusion Criteria: (Both Cases and Controls) 1. Patients requiring active ventilator support 2. Anticoagulant/antiplatelet therapy (for those in the biopsy arm, see Randomization schema. If clinically feasible, patients will be asked to hold their anticoagulants for the muscle biopsy after physician review), 3. Recent gastrointestinal bleeding (<3 months) 4. Advanced organ diseases: congestive heart failure (NYHA class 3 and 4), chronic obstructive pulmonary diseases (COPD) (GOLD stage 3 and 4), chronic kidney disease (Cr>3), metastatic malignancy 5. Medications that alter muscle protein metabolism except systemic corticosteroids 6. Pregnancy 7. Unwillingness/ Inability to sign informed consent

Study Design


Intervention

Dietary Supplement:
ß-hydroxy ß-methyl butyrate (HMB) enriched amino acid
ß-hydroxy ß-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
Balanced amino acid
Balanced amino acid is the balanced mixture of the various essential amino acids.

Locations

Country Name City State
United States Cleveland Clinic Foundation Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in skeletal muscle mass at Day 0 and Day 90 Baseline and Day 90
Primary Number of hospital admissions between Day 0 and Day 90 Baseline and Day 90
See also
  Status Clinical Trial Phase
Completed NCT00708617 - FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease N/A
Completed NCT00990639 - Effect of Candesartan in Alcoholic Liver Fibrosis Phase 1/Phase 2
Recruiting NCT04106518 - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Recruiting NCT04666402 - Integrated Diagnostics for Early Diagnosis of Liver Disease
Recruiting NCT02331745 - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Phase 4
Completed NCT01501162 - Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease Phase 4
Recruiting NCT05895890 - French National MICMAF Cohort
Completed NCT04557774 - Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Recruiting NCT03267069 - Evaluating Alcohol Use in Alcoholic Liver Disease
Recruiting NCT03295812 - Stratification of Chronic Alcoholic Liver Diseases (SCALE Study) N/A
Recruiting NCT05855031 - The Liver Care Trial N/A
Not yet recruiting NCT03503708 - Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease N/A
Completed NCT02796469 - Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis N/A
Completed NCT02140294 - Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease N/A
Recruiting NCT03209791 - Ethanol Induces Skeletal Muscle Autophagy
Recruiting NCT04736966 - Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease Phase 1
Recruiting NCT04400604 - Study of Alcohol-related Liver Disease in Europe
Completed NCT03402256 - Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients N/A
Completed NCT01711125 - Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease Phase 3
Active, not recruiting NCT03863730 - Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota N/A